- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY 3.50 Å
- Oligo State
- hetero-3-3-3-3-3-3-mer
- Ligands
- 21 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN.6: 13 residues within 4Å:- Chain D: E.69, R.71, D.220, P.221, V.263, L.270, N.271, N.383, R.385, C.445, K.446
- Chain N: Q.1
- Ligands: NAG.34
No protein-ligand interaction detected (PLIP)NAG-NAG-BMA-MAN-MAN.14: 11 residues within 4Å:- Chain B: Q.1
- Chain J: R.71, D.220, P.221, L.270, N.271, N.383, R.385, C.445, K.446
- Ligands: NAG.41
1 PLIP interactions:1 interactions with chain J- Hydrogen bonds: J:D.220
NAG-NAG-BMA-MAN-MAN.22: 12 residues within 4Å:- Chain H: Q.1
- Chain P: R.71, D.220, P.221, V.263, L.270, N.271, N.383, R.385, C.445, K.446
- Ligands: NAG.47
2 PLIP interactions:1 interactions with chain P, 1 interactions with chain H- Hydrogen bonds: P:D.220, H:Q.1
- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-3)-alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-MAN-MAN.10: 18 residues within 4Å:- Chain D: N.304, T.306, H.338, N.340, T.413, I.415
- Chain E: R.103, I.104, G.106, V.107, V.108
- Chain F: S.25, N.45, N.46, Q.47, D.62, I.63, N.64
1 PLIP interactions:1 interactions with chain E- Hydrogen bonds: E:V.108
NAG-NAG-BMA-MAN-MAN-MAN-MAN.18: 19 residues within 4Å:- Chain J: N.304, T.306, H.338, N.340, T.413, I.415
- Chain K: R.103, I.104, G.106, V.107, V.108
- Chain L: S.25, N.45, N.46, Q.47, P.61, D.62, I.63, N.64
1 PLIP interactions:1 interactions with chain K- Hydrophobic interactions: K:V.108
NAG-NAG-BMA-MAN-MAN-MAN-MAN.26: 18 residues within 4Å:- Chain P: N.304, T.306, H.338, N.340, T.413, I.415
- Chain Q: R.103, I.104, G.106, V.107, V.108
- Chain R: S.25, N.45, N.46, Q.47, D.62, I.63, N.64
1 PLIP interactions:1 interactions with chain Q- Hydrogen bonds: Q:V.108
- 21 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG.28: 2 residues within 4Å:- Chain A: S.17
- Chain D: N.93
Ligand excluded by PLIPNAG.29: 2 residues within 4Å:- Chain D: T.133, N.165
Ligand excluded by PLIPNAG.30: 1 residues within 4Å:- Chain D: N.206
Ligand excluded by PLIPNAG.31: 4 residues within 4Å:- Chain D: N.243, T.245, E.284
- Ligands: NAG-NAG.7
Ligand excluded by PLIPNAG.32: 3 residues within 4Å:- Chain D: R.343, N.347, I.351
Ligand excluded by PLIPNAG.33: 3 residues within 4Å:- Chain D: R.343, K.395, N.398
Ligand excluded by PLIPNAG.34: 5 residues within 4Å:- Chain D: N.271, S.300, E.302, N.448
- Ligands: NAG-NAG-BMA-MAN-MAN.6
Ligand excluded by PLIPNAG.35: 3 residues within 4Å:- Chain G: S.17
- Chain J: E.92, N.93
Ligand excluded by PLIPNAG.36: 2 residues within 4Å:- Chain J: S.163, N.165
Ligand excluded by PLIPNAG.37: 1 residues within 4Å:- Chain J: N.206
Ligand excluded by PLIPNAG.38: 3 residues within 4Å:- Chain J: N.243, E.284
- Ligands: NAG-NAG.15
Ligand excluded by PLIPNAG.39: 4 residues within 4Å:- Chain J: R.343, E.344, N.347, I.351
Ligand excluded by PLIPNAG.40: 3 residues within 4Å:- Chain J: K.395, N.398, E.399
Ligand excluded by PLIPNAG.41: 3 residues within 4Å:- Chain J: S.300, N.448
- Ligands: NAG-NAG-BMA-MAN-MAN.14
Ligand excluded by PLIPNAG.42: 3 residues within 4Å:- Chain M: S.17
- Chain P: E.92, N.93
Ligand excluded by PLIPNAG.43: 2 residues within 4Å:- Chain P: S.163, N.165
Ligand excluded by PLIPNAG.44: 3 residues within 4Å:- Chain P: V.187, P.188, N.206
Ligand excluded by PLIPNAG.45: 4 residues within 4Å:- Chain P: R.343, E.344, N.347, I.351
Ligand excluded by PLIPNAG.46: 3 residues within 4Å:- Chain P: K.395, N.398, E.399
Ligand excluded by PLIPNAG.47: 4 residues within 4Å:- Chain P: N.271, E.302, N.448
- Ligands: NAG-NAG-BMA-MAN-MAN.22
Ligand excluded by PLIPNAG.48: 5 residues within 4Å:- Chain P: N.243, G.244, T.245, S.283
- Ligands: NAG-NAG.23
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Barnes, C.O. et al., A naturally arising broad and potent CD4-binding site antibody with low somatic mutation. Sci Adv (2022)
- Release Date
- 2022-08-17
- Peptides
- Envelope glycoprotein gp41: AGM
BG24 CDRH2-v2 Fab heavy chain: BHN
BG24 light chain: CIO
Envelope glycoprotein gp160: DJP
10-1074 Fab heavy chain: EKQ
10-1074 light chain: FLR - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
BG
AM
MB
DH
CN
NC
EI
FO
OD
GJ
IP
PE
HK
JQ
QF
LL
KR
R
- Coordinates
- PDB Format
- Method
- ELECTRON MICROSCOPY 3.50 Å
- Oligo State
- hetero-3-3-3-3-3-3-mer
- Ligands
- 21 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA- MAN- MAN: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN- MAN- MAN: alpha-D-mannopyranose-(1-2)-alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-3)-alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 21 x NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Barnes, C.O. et al., A naturally arising broad and potent CD4-binding site antibody with low somatic mutation. Sci Adv (2022)
- Release Date
- 2022-08-17
- Peptides
- Envelope glycoprotein gp41: AGM
BG24 CDRH2-v2 Fab heavy chain: BHN
BG24 light chain: CIO
Envelope glycoprotein gp160: DJP
10-1074 Fab heavy chain: EKQ
10-1074 light chain: FLR - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
BG
AM
MB
DH
CN
NC
EI
FO
OD
GJ
IP
PE
HK
JQ
QF
LL
KR
R